Early response monitoring during [¹⁷⁷Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.

ABSTRACT:

Purpose

To assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with ¹⁷⁷Lutetium-PSMA I&T therapy.

Methods

Single-center, observational study, part of the prospective Swiss national cancer registry study investigating the safety and efficacy of [¹⁷⁷Lu]Lu-PSMA I&T (EKNZ: 2021-01271) in mCRPC patients treated with at least two cycles of [¹⁷⁷Lu]Lu-PSMA I&T 6-weekly. After the first and second cycle quantitated SPECT/CT (Symbia Intevo, Siemens) was acquired 48 h after injection (three fields of view from head to thigh, 5 s/frame) and reconstructed using xQuant® (48i, 1 s, 10-mm Gauss). Image analysis: The PSMA-positive total tumo

SUBMITTER: Neubauer MC 

PROVIDER: S-EPMC10881597 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature